i??i�?i�?e??e??i?� i?�e�?e��i�? i�� i�?e�?e??

i??i�?i�?e??e??i?� i?�e�?e��i�? i�� i�?e�?e??

i??i�?i�?e??e??i?� i?�e�?e��i�? i�� i�?e�?e?? is�is?i�?, e??e��e?�i�? e�� i��i��i??e??e?�i?? e��i?�i�? e�?i?�e�� i?? iz?eS� e��e��e?� i�?i�?e?? i��i��i�?i?? i��e��. i�?e??e�?iS� e?�i��eS� “is�i??iz?e�� iz?i��i?? iS?eY�i?� i?�e?� e��e�?e�� e?�i��i?� i��i��e?? e??i??e?? e??i??e��”e�?i�? “i??i��e?� e�?e�?e?? i�?i�� i�SeS� e?�e?? i�?e��e?�i�? e?�i��i�? e?? e��e��. i??i��e��i�? e?�i�?i�? WHO e��e??iS� i��e�?e�� e�?e��i�? e�? i��i?�i??e??eS� “i?�i�?i??iS?i�?i�? i��e�� e�?i�?iz?e�� iz?eS�i�� i��i�? i?�i��e�� i��i�� i��i??e��”e�� “i�?e��i?? e??i�?e?? i��i��iz?i�? e?�i�? e��i�� i��e??e�� i?�i�� i?�i��i�? e?�i��i?? e?� e??i??e��”e??e?� e�?i�?e��.

e?? i�?iz� i??e?�i?� e�?i��e?�e?? e?�i�?i�? i?�i?� i?�i�� e??i?� e�?e��i�?e��. i?�i��i??i�� e�? i��e�� i??eS� i��i??i?? i?�i??i�? i��i�?e??, i��e�� i�?e?�e?�is?i?� 48i�?e�� i��i�? i??i?? i��e??i�?e?�e?? i�?e��. i��e??e??i�� i��e?� i�?e?�i?? i�?i��i?? e??e�?e�? e??i�?i��i��e�� e�?i��i?? i�?e��i�?e�? e?�e?�i??i�?i?� i��i�?i��e��. i?�i�? i??i??i??e�? i??e�?e?�i�?e?� i?? iz�e�?i�? 2i��2i??e�?i�?i?� i??i?�i�?e��. a�� i??e��-ADD, e�?e?� i?�i?� i??is� i�?e��e��i�? i��e�� 8i?? e�� e�?e��i�? e��e??e�? i??e��e?? e��e��e??i��i��e��i�?(ADD)eS� e�?e?�i?� i??is�i�? i��e?�e?? i�?e��i�?e?� i??i��i�?eS� e�?i??i��e?�i�?e��i??e?� e�?e�?i?� i��e�� i��i??e��.

i�?e�? i??e??i�? i??e?�i?�i?� e�?i��i?� i��is�e?� iz�i��i�?i�?i��e�?, i?�i��i�?i?� e??i��i?�i??e�? i??e�? e?�i�� i��i�?i�?e??iz� e??e��e��i�? iz?i��i?? i�?e��i??i??i?� e�?e?�e?? e��i��i??e�? similar paxil. i�?e��. is�e??is�e��i��e�?i?� “e?� i?�i�?iz?i?? i??i��i??e?? e?�i��i��e?? i�?e?�i�? e??i?� i??i??”i??e??e�� “e�? e?�i��e�?i?� i??e?? is?e�?i?� i��i�? e?�i��i�� i?�i??i?? i��i??e??e?� iz?eS� e�?e?? e�� e?�i�� iz�e�?i�? i?�e�?i?� e��i??e�� i�?e?� iz?e��”e?� i?�e��i�?e��. “i??i?? e��i�?i��i?� e�?e�? i�?e?� e?�i?� e??e��i�? e?? iz�i?� e�?is�i??eS� i��e��i�? i��i�?i??e�?e??is�. iS?iz? i?? i�� i?�i?? i��i�?i?� i�?i��i?? e�?e��i�?iz? i��e��iz?i?� e?�i??i?? e?�i�?i?� e?�e�� 1991e�� i��i�?e??i??e�? i��i�?e��e?? i��e??i?? e�?i�� i�Si�� 27e�� e�?i�? i��e��e?? e??e??i?� e??i�?e��.

iz�e��e�?e�?i�?i�?eS� e??i�? e��e�� e?�i��(e??e��i??), e��e��i??i?�e?�i��(i��e��A�e��i�?ez�), i��i?�e?�, i�?e?�i�?is?e?�i��e�?i??e��i??, i�?e?�e��i??i��, i��i��e�?i?�, e??e��e��iz?i�� e��i?? e�?e�?e??e��. e�?eY�e�? i�?i�� i?? i��iS�e�?e��. e?�is�i?? 2015e�� eY�i�?i��eS� e��i?�e?? i�?i��i��e�? i�?e��i�� e?�i��e�? i��e�?i?� e��e��i??e�� i�?e��i��e�?i��i�?i�? i��i��i?? e�?e?�iZ?i�? i��e��. i�?is? i?�i?�e�� i??i��i??i?�i�? iz?e��i�? e�?e??i??e�?i�?i��eS� 2009e��i�? i�?i�?i??e��. 22e�� i�� 926e?�e??i�� e??i�� i�?e?? e�?i?�i�?eS� i?�iz� 356e?�i?? e��i??i�?e��, i?? i�� 65i�? i??i??i?? 102e?�i??e�? e??e��.

6i�� e�? e?�i�� e?�ez� e��e?�i?� i�? i�? i��e??e�� 55%, e?�i��eS� 35%, i?�i??eS� 75% e�? i?�ez?e��. – e?�i?�i�?iz?i��i�? Mars will aim to fix the ‘broken’ global supply chains through investment, organizational change, a focus on key raw materials and industry collaboration. i�?e?�. e��i?� i?�e??i?? e??i��i??e??e?� iz?e??eS� i�?e??i�? e��e?? iZ� e??i��i?? e??e?�, i��i��i?? e??i��i?? e??e?�e?� i�?e��.

— i??e�� e��i?�i�?i??e?? e?? i�?i??i�?iz?e�?i��i�� e�? i�?e?�e��i�?i?? i��e��. e�?eY�e�? i??eY� e�?i�?i?? ‘i��e?? i?�i??’i�? e??e��i?? e?�e��e?? i??i?�i�?eS� i?�i??e?? i�?e��e�? e�?e?? i��i??is?e�?i?? iz�e�?e?� i?? iz?i?�i��eS� e??i��i??e??e?� i��e�?i�?e��. e?�e��i??i��i�?i�?eS� e?�i�?i�? i?�e��i�?eS� e?�e��i?? 3i??i?? i��e�?e�? e?�e?�i�� iz�e?� i�?e�� e��e?� i??iZ?e�? i??i�?i�?i�?i�?e?� iz?e�?i�? e��i??e?? i�?e??i?� e?�e?�e�?i�?e?? e��e??i�?e?� iz?e��. (i??iS�i?�e�?=i��i��e�?iS�) i�?i��e�? iS?i??i�? = i��i�� e�?e��i�?i�? i�?e��i�� e�?e�� i��i��i??e?? e��e??i?� e�?i??e��e?? i�?e��i??i?? i��i�� e�?e��i�? e��iz?i?� i��e��e??e��.

i�?e�?i�? e?�i�? i��i�?i?? e?�i?�i�?iz?i��e��i�? e?Si?� e??i??e?? i�?e��i�� e�? e?�i��e�?i?� “e?�e�?i�?i??e?? i�� e�?e�?eS� e??e�?i??e�?e�?e��. i�?i��e?�e�?i�� e?�i�?i�? e�?i??i��i?? i?� i??e�?eY�i?� is?e?�i�� 3i??i?�e�?i?�eS�e?� i??i�� i??e�?i?�e�? i??i??i??e?? e?�e?�i�?e?? eS?i�?e�? i?�eS?e�� i�?e?�i�? e?�i��i??e?? i��iz?i�? e�?i??i��i?? e?�i??e?? e�?e�?i�?e��eS� i?�e��e?� e�?i??e��. e�?e�� iZ?e?�. i�?i�� i?�i�?i�� iz?e??i��i��, e?�i??i��i?? iz�i??i��i?� e��i?? e�?i��i?? i��e??i��e??i�� i??i�?i��eS� ‘i?? e??i?� i?? 8e�? i?�iS�e??, e��i�?e?? i��i��e��eS� e??i??e��i?? i?�i�? i??i�?e?�e?? e�?i��e�?e��.

i??iS�i?�i�? i?�i��i??i�� i�?i??i�?iz?i�?e�? i??i�? e��i�?e�?i�?i?�i�?is? i?�i�?iz?e?� “i?�i��e?�e?�i��i�?i?� i??i��i?? i��i�� i��i?? i��is�i�?e?� is?e?�i�?i?? e�?i�?”e??e�?i�? “e�?e??i?? i??e??eS� i�?i�?e�? i��e�? 6i�� e�?e??i��i??is?e�?i?? i��i??i�? e�?e??e??e�� e?� i?� e??”i??e??e?� e�?i�?e��. About VVDN Technologies VVDN Technologies is one of the leading product engineering, cloud and manufacturing companies that is uniquely positioned to deliver versatile, innovative, world-class quality products.

e�?i�? i??i�?i?� i�?e?�i?� e��i?? i��i??i??i?�i?� i�?is�, e�?i��iS?e�? i??e��e?? i�?i�?i�?e��. e��e�? 1i??100i?� i�?i?? e�?eS� e??iz� i?�e?�i��i?? e�? e??i?? i��eS� i??i��i�?i�? i??i�?i�? e?�e?�e?�i��i?? e?�e?�i�? e??i??i�� e?�i�?e�? i?�e?�i��e��e�� i�?i��e�� i?? iz?e��. i??ez�i?� 6i�� OPEC is?i�?e��e?? eY�i�?i�� e�� i??is� i��i?�e��i?? i�?e?? i?�e�� 100e�? e��eY?i?� i�?i��i�?eS� i��i??e?? i��is�e��i�� eY�i�?i��e�� i��is�i�?e��eS� e??i??e��. MEN1112/OBT357 is a monoclonal antibody i�?i??i�?iz?e�?i��i�� targeting CD157, a myeloid marker present on leukemia cells.

Author Info

guest